8-KMaterial AgreementsExhibits & Filings

QUEST DIAGNOSTICS INC 8-K Report, Material Agreement (May 8, 2026)

Filed May 8, 2026For Securities:DGX

Summary

Quest Diagnostics Incorporated (DGX) has announced the issuance of $500 million in aggregate principal amount of 5.000% senior notes due 2036. This offering, detailed under Item 1.01 of their Form 8-K filed on May 8, 2026, represents a significant debt financing event for the company. The notes will mature on June 30, 2036, and will bear interest payable semi-annually. These senior unsecured notes rank equally with existing and future senior unsecured obligations of Quest Diagnostics. The issuance is governed by an indenture, which includes covenants restricting the company and certain subsidiaries from creating specific liens and entering into certain sale and leaseback transactions. Additionally, limitations are placed on the company's ability to consolidate, merge, or transfer substantially all of its assets. In the event of a change of control triggering event, Quest Diagnostics will be obligated to offer to repurchase the notes at 101% of their principal amount plus accrued interest.

Key Highlights

  • 1Quest Diagnostics issued $500 million of 5.000% senior notes due 2036.
  • 2The notes mature on June 30, 2036.
  • 3Interest on the notes will be paid semi-annually, on June 30 and December 30, starting December 30, 2026.
  • 4The notes are senior unsecured obligations, ranking equally with other senior unsecured debt.
  • 5The indenture includes covenants that limit the creation of certain liens and sale and leaseback transactions.
  • 6The indenture also restricts consolidation, merger, or transfer of substantially all of the company's assets.
  • 7A change of control triggering event requires the company to offer to repurchase the notes at 101% of principal plus accrued interest.

Frequently Asked Questions

The filing does not explicitly state the purpose of issuing these senior notes. Typically, such issuances are for general corporate purposes, which could include funding operations, acquisitions, refinancing existing debt, or capital expenditures. Investors would need to refer to future financial reports or investor calls for a detailed explanation.

The covenants limit Quest Diagnostics' flexibility in certain financial and strategic decisions. Specifically, they restrict the ability to incur new liens, enter into sale and leaseback transactions, and to merge or sell substantially all company assets. These restrictions are designed to protect bondholders by preserving the company's asset base and creditworthiness, but they may also limit future growth or restructuring opportunities for the company.

A 'change of control triggering event' is defined in the indenture and generally refers to a significant change in the ownership or control of Quest Diagnostics. If such an event occurs, the company is required to make an offer to repurchase all of the outstanding notes from the holders at a price of 101% of the principal amount, plus any accrued and unpaid interest. This provision aims to protect noteholders from adverse consequences resulting from a change in the company's leadership or ownership.

The issuance of $500 million in senior notes will increase Quest Diagnostics' total debt and leverage on its balance sheet. The impact on its credit rating would depend on various factors, including the company's existing debt levels, its financial performance, and the specific terms and covenants of the notes. Investors should monitor the company's credit ratings from major agencies following this announcement.